SOURCE: Fresh Start Private Management Inc.

Fresh Start Private Management Inc.

December 09, 2010 11:42 ET

Fresh Start Private Naltrexone Implant Procedure Shows Excellent Potential for Reduction in Alcoholism

Naltrexone Reduces the Number of Occasions During Which a Person Is Likely to Drink

LOS ANGELES, CA--(Marketwire - December 9, 2010) - Fresh Start Private (OTCQX: CEYY) (PINKSHEETS: CEYY), a leader in the alcohol treatment and rehabilitation industry, provided data today showing that Naltrexone is effective in the treatment of alcoholism.

According to published results in the Oxford Journals, research indicated that "Naltrexone is superior to placebo. Subjects treated with Naltrexone experience significantly fewer episodes of relapse, and significantly more remain abstinent when compared to placebo-treated subjects {risk difference of relapse rates = -14% [95% confidence interval (CI): -23%, -5%]; and risk difference of abstinence rates = 10% (95% CI: 4%, 16%)} after 12 weeks of treatment. The Naltrexone-treated subjects also consume significantly less alcohol over the study period than do placebo-treated subjects." See http://alcalc.oxfordjournals.org/content/36/6/544.full for the complete results of the study.

A study by Joseph R. Volpicelli, MD, PhD; Arthur I. Alterman, PhD; Motoi Hayashida, MD, ScD; Charles P. O'Brien, MD, PhD, yielded other significant findings as follows:

"Seventy male alcohol-dependent patients participated in a 12-week, double-blind, placebo-controlled trial of Naltrexone hydrochloride (50 mg/d) as an adjunct to treatment following alcohol detoxification. Subjects taking Naltrexone reported significantly less alcohol craving and days in which any alcohol was consumed. During the 12-week study, only 23% of the Naltrexone-treated subjects met the criteria for a relapse, whereas 54.3% of the placebo-treated subjects relapsed. The primary effect of Naltrexone was seen in patients who drank any alcohol while attending outpatient treatment. Nineteen (95%) of the 20 placebo-treated patients relapsed after they sampled alcohol, while only eight (50%) of 16 Naltrexone-treated patients exposed to alcohol met relapse criteria. These results suggest that Naltrexone may be a safe and effective adjunct to treatment in alcohol-dependent subjects, particularly in preventing alcohol relapse."

Fresh Start Private (FSP) is the only alcohol treatment program to offer a single-administration, licensed long-acting, Naltrexone implant procedure. Naltrexone has been approved for use by the FDA within the United States for the treatment of alcohol.

Trained medical doctors insert a specially formulated, biodegradable Naltrexone implant just beneath the skin below the patient's lower abdominal area. The procedure is rapid and requires only local anaesthetic.

FSPs revolutionary procedure works instantly to block the receptors in the brain that crave alcohol. This one-time treatment is affordable and so fast a patient can be back to work the very next day, free from the physical cravings for alcohol.

About Fresh Start Private

Fresh Start Private is an alcohol addiction, alcohol withdrawal, alcohol abuse treatment and alcohol detox rehabilitation company on the leading edge of the alcohol addiction treatment. The Company has licensed a highly effective treatment delivers target therapeutic levels of Naltrexone that significantly reduce patients' cravings for alcohol. Please visit www.freshstartprivate.com

Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Fresh Start filings with the Securities and Exchange Commission.

Contact Information